Pharmacogenomic Testing in a Tertiary Care Outpatient Psychosomatic Medicine Practice

Psychosomatics

Volumn 52, Issue 2, 2011, Pages 141-146

  Rundell, James R ^a   Staab, Jeffrey P ^a   Shinozaki, Gen ^a   Saad Pendergrass, Dahlia ^a   Moore, Katherine ^a   McAlpine, Donald ^a   Mrazek, David ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOOD STABILIZER;

ADULT; ANXIETY DISORDER; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MOOD DISORDER; OUTPATIENT CARE; PHARMACOGENOMIC TESTING; PHARMACOGENOMICS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PSYCHIATRIST; PSYCHOSOMATICS; SELF REPORT; TERTIARY HEALTH CARE; AMBULATORY CARE; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; DECISION MAKING; GENETICS; MENTAL DISEASE; METHODOLOGY; PHARMACOGENETICS; PSYCHOLOGIC TEST; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; STATISTICS;

AMBULATORY CARE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DECISION MAKING; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; LOGISTIC MODELS; MALE; MENTAL DISORDERS; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOSOMATIC MEDICINE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79958098423     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2010.12.023     Document Type: Article

References (22)

1. Mrazek D. Psychiatric Pharmacogenomics 2010, Oxford University Press, New York.
2. Paulose-Ram R., Safran M.A., Jonas B.S., et al. Trends in psychotropic medication use among US adults. Pharmacoepidemiol Drug Safety 2007, 16:560-570.
3. Merikangas K.R., Risch N. Will the genomics revolution revolutionize Psychiatry?. Am J Psychiatry 2003, 160:625-635.
4. Mrazek D.A., Rush A.J., Biernacka J.M., et al. SLC6A4 Variation and Citalopram Response. Neuropsychiatr Genet 2009, 150B:341-351.
5. Murphy D.L., Lerner A., Rudnick G., et al. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol Interv 2004, 4:109-123.
6. Seretti A., Mandelli L., Lorenzi C., et al. Serotonin transporter gene influences the time course of improvement of core depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res 2007, 149:185-193.
7. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
8. Lin E., Chen P.S. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008, 9:935-946.
9. Kohen R., Cain K.C., Mitchell P.H., et al. Association of serotonin transporter gene polymorphisms with poststroke depression. Arch Gen Psychiatry 2008, 65:1296-1302.
10. Henningsen P., Zimmermann T., Sattel H. Medically unexplained physical symptoms, anxiety, and depression: A meta-analytic review. Psychosom Med 2003, 65:528-533.
11. Rundell J.R., Amundsen K., Rummans T.L., et al. Toward defining the scope of psychosomatic medicine practice: Psychosomatic Medicine in an outpatient tertiary care practice setting. Psychosomatics 2008, 49:487-493.
12. Guthrie E. Medically unexplained symptoms in primary care. Adv Psychiatr Treat 2008, 14:432-440.
13. Deepak V., Eby C., Linder M.W., et al. Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thromb Haemost 2005, 93:700-705.
14. Wu X., Hawse J.R., Subramaniam M., et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells. Cancer Res 2009, 69:1722-1727.
15. Rundell J.R., Staab J. Pharmacogenomic testing in an outpatient psychosomatic medicine practice. J Psychosom Res 2009, 66:578. (Abstract).
16. Beck A.T., Steer R.A., Brown G.K. Manual: Beck Depression Inventory 1996, The Psychological Corporation, San Antonio, TX. 2nd ed.
17. Beck A.T., Epstein N., Brown G., et al. An inventory for measuring clinical anxiety-psychometric properties 1998, The Psychological Corporation, San Antonio, TX.
18. Kroenke K., Spitzer R.L., Williams J.B.W. The PHQ-9: Validity of a brief depression severity measure. J Gen Internal Med 2001, 16:60-613.
19. Babor T.F., de la Fuente J.R., Saunders J., et al. AUDIT: The Alcohol Use Disorders Identification Test-guidelines for use in primary health care 1992, World Health Organization, Geneva Switzerland.
20. Lecrubier D.V., Sheehan E., Weiller P., et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. Eur Psychiatry 1997, 12:224.
21. Wu A.H., Babic N., Yeo K.T.J. Implementation of pharmacogenomics into the clinical practice of therapeutics: Issues for the clinician and the laboratorian. Personalized Med 2009, 6:315-327.
22. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003, 53:649-659.